Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.52−0.25 (-2.56%)
Close on Nov 19, 2026Market cap $1.33BP/E –Yield –
Intellia Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Intellia Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$348.69M. For fiscal 2025 it was -$395.87M. The highest annual figure on record is $29.94M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$395.87M | – |
| FY2024 | Dec 31, 2024 | -$354.66M | – |
| FY2023 | Dec 31, 2023 | -$408.07M | – |
| FY2022 | Dec 31, 2022 | -$346.85M | – |
| FY2021 | Dec 31, 2021 | -$237.79M | – |
| FY2020 | Dec 31, 2020 | -$53.50M | – |
| FY2019 | Dec 31, 2019 | -$110.03M | – |
| FY2018 | Dec 31, 2018 | -$67.62M | – |
| FY2017 | Dec 31, 2017 | -$75.37M | -351.7% |
| FY2016 | Dec 31, 2016 | $29.94M | – |
| FY2015 | Dec 31, 2015 | -$4.32M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$84.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$117.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$69.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$76.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$99.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$149.67M | – |
| Q4 FY2024 | Dec 31, 2024 | -$86.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$86.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$59.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$123.17M | – |
| Q4 FY2023 | Dec 31, 2023 | -$94.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$105.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$94.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$113.16M | – |
| Q4 FY2022 | Dec 31, 2022 | -$93.78M | – |
| Q3 FY2022 | Sep 30, 2022 | -$82.76M | – |
| Q2 FY2022 | Jun 30, 2022 | -$89.07M | – |
| Q1 FY2022 | Mar 31, 2022 | -$81.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$57.52M | – |
| Q3 FY2021 | Sep 30, 2021 | -$69.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.92M | -199.2% |
| Q1 FY2021 | Mar 31, 2021 | -$54.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$41.23M | – |
| Q3 FY2020 | Sep 30, 2020 | -$29.26M | – |
| Q2 FY2020 | Jun 30, 2020 | $56.38M | – |
| Q1 FY2020 | Mar 31, 2020 | -$39.39M | – |
| Q4 FY2019 | Dec 31, 2019 | -$31.23M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.20M | – |
| Q2 FY2019 | Jun 30, 2019 | -$28.62M | – |
| Q1 FY2019 | Mar 31, 2019 | -$22.99M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.13M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.47M | – |
| Q2 FY2018 | Jun 30, 2018 | -$23.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$19.62M | – |
| Q4 FY2017 | Dec 31, 2017 | -$23.70M | – |
| Q3 FY2017 | Sep 30, 2017 | -$19.15M | – |
| Q2 FY2017 | Jun 30, 2017 | -$16.95M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.56M | – |
| Q4 FY2016 | Dec 31, 2016 | -$17.82M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.22M | – |
See a number that looks wrong?